Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to reignite immune attack on Hard-to-Treat cancers

NCT ID NCT04471987

Recruiting now Disease control Sponsor: Philogen S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called IL12-L19L19 (Dodekin) in 80 adults with advanced or metastatic solid tumors that have stopped responding to standard immunotherapy. The drug combines an antibody with an immune-boosting protein to target and attack cancer cells. The main goals are to check safety, find the right dose, and look for early signs that the drug might shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
IL12-L19L19 (Dodekin), a drug that combines an antibody with a protein to boost the immune system against tumors
What this could lead to
If successful, this could lead to a new treatment option for patients with advanced solid tumors who have stopped responding to standard immunotherapy.
What could go wrong
This is an early Phase I trial with only 80 participants, focused on safety and dosing. It is too small to prove effectiveness, and side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma metastatic carcinoma metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga

    NOT_YET_RECRUITING

    Orbassano, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    RECRUITING

    Milan, 20133, Italy

  • Geneva University Hospital, Oncology Department

    RECRUITING

    Geneva, Canton of Geneva, 1211, Switzerland

  • IEO - Istituto Europeo di Oncologia

    RECRUITING

    Milan, Italy, Italy

  • Insel Gruppe AG

    RECRUITING

    Bern, Canton of Bern, 3010, Switzerland

  • Oncology Institute of Southern Switzerland

    RECRUITING

    Bellinzona, 6500, Switzerland

  • Universitaetsklinik Hamburg-Eppendorf

    RECRUITING

    Hamburg, Free and Hanseatic City of Hamburg, Germany

  • Universitätsklinikum Heidelberg, Nationalen Centrum für Tumorerkrankungen (NCT), Dermatoonkologie

    RECRUITING

    Heidelberg, Heidelberg, 69120, Germany

  • Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie

    RECRUITING

    Leipzig, Leipzig, 04103, Germany

  • Universitätsklinikum Tübingen, Klinik für Innere Medizin VIII Medizinische Onkologie und Pneumologie

    RECRUITING

    Tübingen, 72076, Germany

  • Universitätsspital Basel

    RECRUITING

    Basel, Basel, CH-4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.